Institute of Microbiology, University of Lausanne and University Hospital Center, CH-1011 Lausanne, Switzerland.
Antimicrob Agents Chemother. 2010 Apr;54(4):1476-83. doi: 10.1128/AAC.01645-09. Epub 2010 Jan 19.
Principal mechanisms of resistance to azole antifungals include the upregulation of multidrug transporters and the modification of the target enzyme, a cytochrome P450 (Erg11) involved in the 14alpha-demethylation of ergosterol. These mechanisms are often combined in azole-resistant Candida albicans isolates recovered from patients. However, the precise contributions of individual mechanisms to C. albicans resistance to specific azoles have been difficult to establish because of the technical difficulties in the genetic manipulation of this diploid species. Recent advances have made genetic manipulations easier, and we therefore undertook the genetic dissection of resistance mechanisms in an azole-resistant clinical isolate. This isolate (DSY296) upregulates the multidrug transporter genes CDR1 and CDR2 and has acquired a G464S substitution in both ERG11 alleles. In DSY296, inactivation of TAC1, a transcription factor containing a gain-of-function mutation, followed by sequential replacement of ERG11 mutant alleles with wild-type alleles, restored azole susceptibility to the levels measured for a parent azole-susceptible isolate (DSY294). These sequential genetic manipulations not only demonstrated that these two resistance mechanisms were those responsible for the development of resistance in DSY296 but also indicated that the quantitative level of resistance as measured in vitro by MIC determinations was a function of the number of genetic resistance mechanisms operating in any strain. The engineered strains were also tested for their responses to fluconazole treatment in a novel 3-day model of invasive C. albicans infection of mice. Fifty percent effective doses (ED(50)s) of fluconazole were highest for DSY296 and decreased proportionally with the sequential removal of each resistance mechanism. However, while the fold differences in ED(50) were proportional to the fold differences in MICs, their magnitude was lower than that measured in vitro and depended on the specific resistance mechanism operating.
唑类抗真菌药物耐药的主要机制包括多药转运蛋白的上调和靶酶(参与麦角固醇 14α-去甲基化的细胞色素 P450(Erg11))的修饰。这些机制通常在从患者中回收的唑类耐药白色念珠菌分离株中结合存在。然而,由于在这种二倍体物种中进行遗传操作的技术困难,因此很难确定个体机制对白色念珠菌对特定唑类药物的耐药性的确切贡献。最近的进展使遗传操作变得更加容易,因此我们对唑类耐药临床分离株中的耐药机制进行了遗传剖析。该分离株(DSY296)上调多药转运基因 CDR1 和 CDR2,并且在两个 ERG11 等位基因中都获得了 G464S 取代。在 DSY296 中,失活含有功能获得突变的转录因子 TAC1,然后依次用野生型等位基因替换 ERG11 突变等位基因,将唑类药物敏感性恢复到亲代唑类药物敏感分离株(DSY294)测量的水平。这些连续的遗传操作不仅证明了这两种耐药机制是导致 DSY296 耐药性发展的原因,而且表明通过 MIC 测定体外测量的耐药性定量水平是任何菌株中起作用的遗传耐药机制数量的函数。还在一种新的白色念珠菌侵袭性感染小鼠的 3 天模型中测试了工程菌株对氟康唑治疗的反应。氟康唑的 50%有效剂量(ED50)对 DSY296 最高,并随着每个耐药机制的依次去除而成比例降低。然而,虽然 ED50 的倍差与 MIC 的倍差成比例,但它们的幅度低于体外测量值,并且取决于起作用的特定耐药机制。